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A B S T R A C T
Palbociclib has been shown to be a highly eﬀective therapy in hormone receptor positive metastatic breast
cancer when used in combination with letrozole or fulvestrant. Grade 3/4 neutropenia is a common side eﬀect
although febrile neutropenia is relatively uncommon. Insuﬃcient data exist to describe the hematological safety
of palbociclib in African American women (AAW) known to have a high incidence of benign ethnic neutropenia
(BEN). PALOMA 1, 2 and 3, the initial phase II/III studies that led to the U.S. Food and Drug Administration
(FDA) approval of palbociclib in metastatic breast cancer, only included participants with baseline absolute
neutrophil count (ANC) of 1500/mm3 or higher. African American women (AAW) were underrepresented in the
PALOMA trials and this may be partially explained by strict requirements for minimal ANC ≥1500/mm3. The
ANC of 1500/mm3 for initiation of treatment in those with BEN has been previously challenged. In this study, we
propose to lower the ANC cutoﬀ for enrollment to 1000/mm3. PALINA (NCT02692755) is a phase II, single arm,
multicenter clinical trial that will enroll 35 patients. The primary endpoint is to assess the proportion of patients
who complete therapy without the development of febrile neutropenia or treatment discontinuation due to
neutropenia. The secondary endpoints include number of patients who required dose delays or dose reductions
in palbociclib attributed to neutropenia, rate of grade 3/4 neutropenia, clinical beneﬁt rate at 24 weeks, the
association between metabolite and exosomal signature with disease response and the association between
baseline ANC prior to cancer diagnosis and the Duﬀy Null polymorphism (SNP rs2814778) with hematological
safety. PALINA will provide important information about the hematologic safety of palbociclib in AAW with
advanced breast cancer.
1. Introduction
Approximately one-third of patients with hormone receptor (HR)
positive human epidermal growth factor receptor 2 (HER2) negative
tumors experience disease recurrence despite being initially diagnosed
with early stage disease [1]. Palbociclib is a highly selective oral re-
versible inhibitor of cyclin-dependent kinases (CDK) 4 and 6. Palboci-
clib has been approved for women with advanced or metastatic HR-
positive HER2-negative breast cancer in combination with either
letrozole or fulvestrant [2,3]. Grade 3/4 neutropenia was the most
commonly noted toxicity in the clinical trials that led to the approval of
palbociclib (in up to 65% of patients), however, febrile neutropenia was
relatively uncommon [4–6]. In these trials, an absolute neutrophil
count (ANC) of at least 1500/mm3 was required for enrollment [4–6].
This cutoﬀ could unnecessarily exclude patients with benign ethnic
neutropenia (BEN) which aﬀects 25–50% of individuals of African
descent and some ethnic groups in the Middle East [7,8]. Due to a
variety of reasons that include general lack of awareness of trials,
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mistrust in the medical system, communication gaps and structural
barriers such as transportation, childcare and access to health care
[9,10], African American women (AAW) continue to be under-
represented in clinical trials. Without representation in trials, the lack
of appreciation of genetic factors particular to African-Americans and
other minority communities will continue to increase [11]. The di-
versity gap that results from low minority accrual in clinical trials can
lead to sub-optimal development of new medicines, compromise the
generalization of clinical trial results and further exacerbate minority
health disparities.
1.1. Study rationale
In this study, we propose to evaluate the hematological safety of
palbociclib in combination with letrozole or fulvestrant in AAW with
HR-positive, HER2-negative advanced breast cancer. Currently, there is
insuﬃcient data to describe the hematological safety of palbociclib in
this population and the strict requirement of ANC of 1500/mm3 for
initiation of treatment could exclude patients with BEN, which is
common in this population [12,13]. Therefore we propose to lower the
ANC cutoﬀ for the enrollment on this trial to 1000/mm3 or higher.
Presence of Duﬀy Null Polymorphism as a predictive marker for neu-
trophil count will be assessed at baseline.
2. PALINA study design
The PALINA study (NCT02692755) is a phase II, single arm, mul-
ticenter clinical trial designed to assess the proportion of patients who
complete therapy without the development of febrile neutropenia or
treatment discontinuation due to neutropenia (primary endpoint). We
will also assess the following as secondary endpoints: number of pa-
tients who required dose delays or dose reductions in palbociclib at-
tributed to neutropenia, rate of grade 3/4 neutropenia, clinical beneﬁt
rate at 24 weeks, the association between metabolite and exosomal
signature with disease response and the association between baseline
ANC prior to cancer diagnosis and the Duﬀy Null polymorphism (SNP
rs2814778) with hematological safety. The Institutional Review Board
at Georgetown University Medical Center has approved the study.
2.1. Treatment
Patients enrolled with baseline ANC of 1500/mm3 or greater will
receive palbociclib 125mg daily for 21 days followed by 7 days oﬀ in
addition to letrozole 2.5mg daily or fulvestrant 500mg on days 1, 15,
and 29, and as maintenance dose of 500mg every 28 days. If baseline
ANC 1000–1499/mm3, initial dose of palbociclib will be 100mg daily
21 days on, 7 days oﬀ and increase to 125mg after cycle 2 if well
tolerated (Fig. 1). Palbociclib recommended dose modiﬁcations for
hematological related toxicities requiring treatment interruption/delay
follow the FDA label and are described in Table 1.
2.2. Correlative studies
Presence of Duﬀy Null Polymorphism as a predictive marker for
neutrophil count will be assessed at baseline. Metabolite and exosomal
signature (proteins and RNA) of drug resistance will be evaluated at
diﬀerent time points (every 14 days for ﬁrst two cycles and then every
28 days while on study). Untargeted metabolomics analysis of serum
may allow identiﬁcation of metabolite markers of endocrine resistance
by comparing metabolite proﬁle of responders to that of non-re-
sponders. In addition, the characterization of exosomes has previously
been shown to be a potential predictive biomarker of drug resistance in
the clinic [14,15]. Metabolomics analysis of the serum will be per-
formed using ultra-performance liquid chromatography mass spectro-
meter (UPLC MS) and gas chromatography-mass spectrometry (GC MS).
Analysis will provide a global distribution of speciﬁc metabolites in
patients' serum at the beginning and end of the study. To perform an
exosomal signature of drug resistance, exosomes will be isolated from
serum followed by puriﬁcation of RNA and proteins for next generation
sequencing (NGS) and mass spectrometry analysis, respectively. RNA-
seq and proteomics proﬁle from serum samples of patients will be
compared with patient's tumor assessments to determine biochemical
changes associated with response to palbociclib.
2.3. Key inclusion criteria
Self-identiﬁed Black, African or African American women of ≥18
years of age with HR-positive HER2-negative advanced adenocarci-
noma of the breast. Patients must have an Eastern Cooperative
Oncology Group performance status of 0–2. Adequate bone marrow
function deﬁned as ANC ≥1000/mm3, Platelets ≥100,000/mm3 and
hemoglobin ≥9 g/dL (90 g/L).
2.4. Key exclusion criteria
Patients with previous use CDK4/6 inhibitor or those currently on
potent inhibitors or inducers of CYP3A4 are excluded. Also, patients
with active uncontrolled or symptomatic brain metastases are excluded.
2.5. Statistical considerations
A total of 35 patients will be recruited across MedStar Cancer
Network in the greater Washington, DC area, the University of Chicago
and Thomas Jeﬀerson University in Philadelphia. The ﬁrst patient was
enrolled in November 2016 and we anticipate the enrollment to be
completed within 24 months. Simon's two-stage design with a max-
imum of 35 patients is used. The null hypothesis that the true com-
pletion rate is 60% will be tested against a one-sided alternative. This
design yields a type I error rate of 0.05 and power of 80% when the true
completion rate is 80%. Early stopping rules will be incorporated for
safety based on febrile neutropenia. Safety monitoring plan consists of a
Data Safety Monitoring Committee (DSMC).
3. Conclusions
Women of African descent are often underrepresented in clinical
trials and this was also veriﬁed in the clinical trials that led to the
approval of palbociclib for the treatment of HR positive advanced
breast cancer. The design of a trial such as the PALINA study that mi-
mics real-world conditions will hopefully address barriers to enrollment
and help answer the question of the hematological safety of palbociclib
in African American patients [12]. The results of this novel trial will
provide important contribution to close the gap in cancer health dis-
parities and further advance towards the promise of personalized
medicine.Fig. 1. Study design.
F. Lynce et al. Contemporary Clinical Trials Communications 10 (2018) 190–192
191
Disclosures
This research is funded by an ASPIRE Breast Cancer Research Award
from Pﬁzer (WI208808).
Appendix A. Supplementary data
Supplementary data related to this article can be found at http://dx.
doi.org/10.1016/j.conctc.2018.05.012.
References
[1] Eﬀects of chemotherapy and hormonal therapy for early breast cancer on recur-
rence and 15-year survival: an overview of the randomised trials, Lancet (London,
England) 365 (9472) (May 14-20 2005) 1687–1717.
[2] A.J. Walker, S. Wedam, L. Amiri-Kordestani, et al., FDA approval of palbociclib in
combination with fulvestrant for the treatment of hormone receptor-positive,
HER2-negative metastatic breast cancer, Clin. Canc. Res. Oﬃcial J. Amer. Assoc.
Canc. Res. 22 (20) (Oct 15 2016) 4968–4972.
[3] J.A. Beaver, L. Amiri-Kordestani, R. Charlab, et al., FDA approval: palbociclib for
the treatment of postmenopausal patients with estrogen receptor-positive, HER2-
negative metastatic breast cancer, Clin. Canc. Res. Oﬃcial J. Amer. Assoc. Canc.
Res. 21 (21) (Nov 01 2015) 4760–4766.
[4] R.S. Finn, J.P. Crown, I. Lang, et al., The cyclin-dependent kinase 4/6 inhibitor
palbociclib in combination with letrozole versus letrozole alone as ﬁrst-line treat-
ment of oestrogen receptor-positive, HER2-negative, advanced breast cancer
(PALOMA-1/TRIO-18): a randomised phase 2 study, Lancet Oncol. 16 (1) (Jan
2015) 25–35.
[5] A study of Palbociclib (PD-0332991) + letrozole vs. letrozole for ﬁrst line treat-
ment of postmenopausal women with ER/HER2- advanced breast cancer (PALOMA-
2), Available at: https://clinicaltrials.gov/ct2/show/NCT01740427.
[6] S. Verma, C.H. Bartlett, P. Schnell, et al., Palbociclib in combination with fulves-
trant in women with hormone receptor-positive/HER2-negative advanced meta-
static breast cancer: detailed safety analysis from a multicenter, randomized, pla-
cebo-controlled, phase III study (PALOMA-3), Oncol. 21 (10) (Oct 2016)
1165–1175.
[7] Haddy TB, Rana SR, Castro O. Benign ethnic neutropenia: what is a normal absolute
neutrophil count? J. Lab. Clin. Med. 133(1):15–22.
[8] D. Reich, M.A. Nalls, W.H. Kao, et al., Reduced neutrophil count in people of
African descent is due to a regulatory variant in the Duﬀy antigen receptor for
chemokines gene, PLoS Genet. 5 (1) (Jan 2009) e1000360.
[9] Y. Harris, P.B. Gorelick, P. Samuels, et al., Why African Americans may not be
participating in clinical trials, J. Natl. Med. Assoc. 88 (10) (Oct 1996) 630–634.
[10] D. Rivers, E.M. August, I. Sehovic, B. Lee Green, G.P. Quinn, A systematic review of
the factors inﬂuencing African Americans' participation in cancer clinical trials,
Contemp. Clin. Trials 35 (2) (2013 Jul) 13–32.
[11] M.S. Chen Jr., P.N. Lara, J.H. Dang, et al., Twenty years post-NIH Revitalization
Act: enhancing minority participation in clinical trials (EMPaCT): laying the
groundwork for improving minority clinical trial accrual: renewing the case for
enhancing minority participation in cancer clinical trials, Cancer 120 (Suppl 7) (Apr
01 2014) 1091–1096.
[12] M.M. Hsieh, J.F. Tisdale, G.P. Rodgers, et al., Neutrophil count in African
Americans: lowering the target cutoﬀ to initiate or resume chemotherapy? J. Clin.
Oncol. Oﬃcial J. Amer. Soc. Clin. Oncol. 28 (10) (Apr 01 2010) 1633–1637.
[13] D.L. Kelly, J. Kreyenbuhl, L. Dixon, et al., Clozapine underutilization and dis-
continuation in African Americans due to leucopenia, Schizophr. Bull. 33 (5) (Sep
2007) 1221–1224.
[14] D.D. Yu, Y. Wu, X.H. Zhang, et al., Exosomes from adriamycin-resistant breast
cancer cells transmit drug resistance partly by delivering miR-222, Tumour Biology
J. Int. Soc. Oncodevelopmental Biol. Med. 37 (3) (Mar 2016) 3227–3235.
[15] M.M. Lv, X.Y. Zhu, W.X. Chen, et al., Exosomes mediate drug resistance transfer in
MCF-7 breast cancer cells and a probable mechanism is delivery of P-glycoprotein,
Tumour biology J. Int. Soc. Oncodevelopmental Biol. Med. 35 (11) (Nov 2014)
10773–10779.
Table 1
Dose modiﬁcation and management for hematologic toxicities.
CTCAE grade Dose Modiﬁcations
Grade 1 or 2 No dose adjustment is required.
Grade 3 neutropenia (ANC<1000/mm3),
thrombocytopenia (PLC < 50,000/mm3) or anemia (Hgb < 8 g/dL)
No dose adjustment is required. Consider repeating CBC monitoring one week later.
Withhold initiation of next cycle until recovery to Grade ≤2.
Grade 3 neutropenia (< 1000 to 500/mm3) + fever ≥38.5 °C and/or infection Withhold palbociclib and initiation of next cycle until recovery to Grade ≤2 (≥1000/
mm3). Resume at next lower dose.
Grade 4 neutropenia (ANC<500/mm3), thrombocytopenia (PLC < 25,000/mm3) or
anemia (life threatening consequences)
Withhold palbociclib and initiation of next cycle until recovery to Grade≤2. Resume at
next lower dose.
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